1 Broadway # 14, Cambridge, MA 02142
Cancer patients who are obese face a greater risk of dying from cancer compared to non-obese patients (Calle, 2003). Excess visceral adiposity is believed to contribute to metastasis and progression of cancer via multiple mechanisms: increased secretion of the adipose tissue hormone leptin, decreased secretion of adiponectin, increased production of estrogen in adipose tissue, and elevated insulin (secondary to peripheral insulin resistance) as well as the local effects of inflammatory cytokines (Gucalp, 2016).
Women with breast cancer and diabetes have a greater risk for all-cause and cancer-specific mortality and are less likely to receive chemotherapy and radiotherapy compared with women with breast cancer alone, according to researchers.
About 40 percent of all cancers in the United States -- more than 630,000 in all -- are associated with excess weight, health officials said Tuesday, urging a renewed focus on prevention. The rates of these overweight- and obesity-related cancers are rising, in contrast to the overall rate of new cancer cases which has dropped since the 1990s.
"When assessing cancer risk, body mass index (BMI) and fat percentage may not be adequate measures as they fail to assess the distribution of fat mass," she explained. "Avoiding central obesity may confer the best protection."
Obesity has become one of the leading preventable causes of cancer. Yet, the mechanisms of how obesity and associated systemic inflammation can promote cancer progression remain poorly understood. In a new study, researchers found that the cytokines interleukin 5 (IL-5) and granulocyte macrophage colony-stimulating factor (GM-CSF) are induced in obesity and, in obese mice, this leads to lung neutrophilia and supports breast cancer metastasis to the lung. Quail, Olson et al. used mouse models of obesity, induced by a high-fat diet (diet-induced obesity, DIO mice) or leptin deficiency (ob/ ob mice), to study how inflammation in obesity is linked to breast cancer metastasis.
Research is still lacking to support a link between obesity and an increased risk of developing all types of cancer. Nevertheless, a review1 of more than 1,000 epidemiologic studies by the International Agency for Research on Cancer (IARC), a division of the World Health Organization, examining the preventive effects of weight control on cancer risk […]
The ASCO Annual Meeting brings together more than 30,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field.
Type 2 diabetes mellitus (T2DM) is becoming increasingly prevalent worldwide. Epidemiologic data suggest that T2DM is associated with an increased incidence and mortality from many cancers. The purpose of this review is to discuss the links between diabetes and cancer, the effects of various antidiabetic medications on cancer incidence and mortality, and the effects of anticancer therapies on diabetes.
There is growing evidence that inflammation is a central and reversible mechanism through which obesity promotes cancer risk and progression.
The association of obesity with cancer, increasingly recognized in both lay and medical communities and underscored by the ongoing obesity epidemic, has stimulated a large body of research and led to calls for programs to minimize any potential impact of obesity on cancer